Compare Citius Pharmaceuticals Inc (CTXR) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $25.35 (market cap $141.25M). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is far larger — about 10.4× Citius Pharmaceuticals Inc's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| CTXR | KOLD | |
|---|---|---|
Market Cap | $13.62M | $141.25M |
Volume | 132,438 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $49.39 |
52-Week Low | $0.48 | $13.58 |
Typical Hold Time | 16 Days | 10 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend, though oscillators remain neutral. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy sector sentiment. The stock currently trades near key support levels with resistance forming around $25-26.
The outlook remains challenging with bearish technical indicators and fundamental headwinds in the natural gas sector. Investment opportunities exist for contrarian investors betting on energy market recovery, but risks include continued production growth and weather-dependent demand. The stock's performance will likely track natural gas price movements and broader energy market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
